A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2018

At a glance

  • Drugs Zolmitriptan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Sponsors Amneal Pharmaceuticals; IMPAX Laboratories
  • Most Recent Events

    • 07 May 2018 According to a Amneal Pharmaceuticals media release, Impax Laboratories has combined its business (merged) with Amneal Pharmaceuticals LLC, to form Amneal Pharmaceuticals Inc.
    • 16 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top